Seeking Alpha
 

Allos Therapeutics, Inc. (ALTH)

- NASDAQ
ALTH is defunct.
  • Aug. 29, 2012, 11:52 AM
    Spectrum Pharmaceuticals (SPPI +4.6%) says the FTC has cleared its acquisition of Allos Therapeutics (ALTH +1.1%). SPPI has been looking to boost its hematology franchise, and has been chasing ALTH over most of the summer in pursuit of its lymphoma drug Folotyn. The tender offer for Allos shares is slated to expire at 5pm EST on September 4, 2012.
    | 3 Comments
  • Jul. 17, 2012, 1:02 PM
    Allos (ALTH) storms 19.6% higher after Spectrum (SPPI -0.9%) provides reassurances that its $206M+ acquisition of Allos is progressing well and that the company was "very happy with everything." Allos' shares plunged 20% yesterday on rumors that the deal had fallen through.
    | 1 Comment
  • Apr. 5, 2012, 8:52 AM
    Allos Therapeutics (ALTH) roars to a 27.9% gain premarket up to $1.85 a share after Spectrum Pharmaceuticals (SPPI) agrees to buy the company. The trading price falls in the range between the offering price of $1.82/share and the $1.93-a-share value of the deal with kickers. Shares of SPPI -9.9% premarket, reeling from a negative results from a trial on apaziquone.
    | Comment!
  • Apr. 5, 2012, 8:50 AM
    Premarket gainers: ALTH +28%. LLEN +14%. WOLF +11%. BBBY +5%. ZLCS +4%. GFI +3%. TLK +3%.
    Losers: PLCM -19%. CKEC -10%. SPPI -10%. HOV -5%. ALU -5%. VE -4%. ING -3%. STD -3%.
    | 1 Comment
  • Apr. 5, 2012, 7:16 AM
    Spectrum Pharmaceuticals (SPPI) buys Allos Therapeutics (ALTH) for $1.82 a share in a deal that also includes a $0.11/share contingency if certain European regulatory approvals and milestones for Folotyn are hit. The company expects the acquisition to be accretive in Q4.
    | Comment!
  • Mar. 6, 2012, 4:15 PM
    Allos Therapeutics (ALTH): Q4 EPS of -$0.01 beats by $0.08. Revenue of $15.4M (+44.4% Y/Y) in-line. Shares -2.9% AH. (PR)
    | Comment!
  • Jan. 31, 2012, 8:20 AM
    Shares of Allos Therapeutics (ALTH) move up 8.1% premarket on chatter that the firm could be a beneficiary of the decision by Cell Therapeutics (CTIC) to withdraw its NDA with the FDA.
    | Comment!
  • Jan. 23, 2012, 3:48 PM
    Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%.
    | Comment!
  • Jan. 23, 2012, 9:53 AM
    Shares of AMAG Pharmaceuticals (AMG -4.4%) move lower after the firm takes on a downgrade from JPMorgan to Underweight. The ratings move on AMAG is part of a larger sector call that includes VPHM, ACOR, AMGN, and ALTH all getting slashed on valuation.
    | Comment!
  • Jan. 20, 2012, 9:15 AM
    Premarket gainers: INSM +24%. ASIA +16%. SWKS +6%. URRE +6%. MPC +5%. BCS +4%. CTIC +4%. RBS +3%. IBM +3%. SAVE +3%. MSFT +3%.
    Losers: ALTH -20%. GOOG -8%. AONE -7%. SQNM -6%. HTGC -6%. COF -6%. PH -5%. ZIOP -5%. MMLP -5%. BWP -4%. CX -4%. CUK -4%. ARCC -4%. CCL -3%. NVS -3%. MT -3%.
    | Comment!
  • Jan. 20, 2012, 8:42 AM
    Allos Therapeutics (ALTH) -19.3% premarket after receiving a negative opinion from European regulators on its Folotyn treatment for patients with peripheral T-cell lymphoma. The company says it plans to submit a request for re-examination of the opinion within two weeks.
    | Comment!
  • Oct. 21, 2011, 9:59 AM
    Allos Therapeutics (ALTH -6.2%) and AMAG Pharmaceuticals (AMAG +4.5%) terminate their merger agreement after AMAG shareholders fail to approve the issuance of shares of common stock to ALTH stockholders.
    | 1 Comment
  • Oct. 10, 2011, 2:44 PM
    Allos Therapeutics (ALTH -18%) takes a hit after it says an anonymous bidder has withdrawn a takeover offer of $2.20 a share. The company says it will continue working toward with AMAG Pharmaceuticals (AMAG +2.3%).
    | 1 Comment
  • Sep. 21, 2011, 9:33 AM
    Allos Therapeutics (ALTH) is up 11%, and AMAG Pharmaceuticals (AMAG) up 2%, after Allos discloses it's received a $2.20/share offer to acquire the company, though it warns its board has not recommended the proposal. AMAG's planned buyout of Allos has been threatened by shareholder opposition following MSMB Capital's offer for AMAG.
    | Comment!
  • Sep. 21, 2011, 9:15 AM
    Premarket gainers: OREX +66%. ALTH +15%. ARNA +9%. ORCL +5%. ADBE +5%. HLS +5%. CS +4%. MCP +4%. ALU +3%. YRCW +3%.
    Losers: WLT -13%. ANR -10%. PCX -5%. ACI -5%. NUVA -4%. BTU -4%. -3%. TCK -3%.
    | Comment!
  • Sep. 7, 2011, 8:54 AM
    The proposed $686M merger between Amag Pharmaceuticals (AMAG) and Allos Therapeutics (ALTH) could be scuttled after two large shareholders of AMAG threaten to vote against the transaction. Reports say the investors are evaluating if a management shakeup or supporting a tender offer from MSMB Capital might be better options. AMAG +8.1% premarket.
    | Comment!
Visit Seeking Alpha's
Company Description
We incorporated in the Commonwealth of Virginia on September 1, 1992 as HemoTech Sciences, Inc. and filed amended Articles of Incorporation to change our name to Allos Therapeutics, Inc. on October 19, 1994. We reincorporated in Delaware on October 28, 1996. We completed our initial public... More